Literature DB >> 7920209

Phenotyping of CYP1A2 in Japanese population by analysis of caffeine urinary metabolites: absence of mutation prescribing the phenotype in the CYP1A2 gene.

M Nakajima1, T Yokoi, M Mizutani, S Shin, F F Kadlubar, T Kamataki.   

Abstract

Caffeine has been used as a metabolic probe to determine the relative levels of CYP1A2 activity in different individuals, since this compound is specifically 3-demethylated by CYP1A2. Urine specimen obtained at a 4-5-h interval after caffeine ingestion from 205 Japanese were analyzed using the [1,7-dimethyluric acid + 1,7-dimethylxanthine]/caffeine (1,3,7-trimethylxanthine) ratio, which better correlated with the rate constant for caffeine 3-demethylation than other ratios. The probit analyses of nonsmokers (n = 147) and smokers (n = 58) suggested that the CYP1A2 activity was not normally distributed and appeared bimodal. The breakpoints were at 5.0 and 6.0 of (1,7-dimethyluric acid + 1,7-dimethylxanthine)/1,3,7-trimethylxanthine ratio in nonsmokers and smokers, respectively. The bimodal probit plot suggested the existence of poor and extensive phenotypes. The percentage of individuals with the poor phenotype in Japanese was 14.1%. Induction of CYP1A2 by cigarette smoking was confirmed by the higher molar ratio observed in smokers (P < 0.0001). The CYP1A2 ratio was also higher in males than in females (P = 0.04). A reproducibility study of 12 subjects in an 11 month interval period showed that intraindividual variability did not alter this CYP1A2 phenotypic classification. Family study in eight pedigrees suggested that the poor phenotype of CYP1A2 inherited as an autosomal recessive trait. The sequences of CYP1A2 gene from poor and extensive metabolizers were analyzed. Although no differences of nucleotide sequence were observed in exons, exon-intron junctions and 5'-flanking regions (up to -2.6 kilobases) of CYP1A2 gene between each phenotype, there were some sequences which differed from the previous reported data. This is the first report in which the CYP1A2 phenotype and a genetic polymorphism in the CYP1A2 gene were comparably investigated.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7920209

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  28 in total

Review 1.  Pharmacogenetics of asthma.

Authors:  A Fenech; Ian P Hall
Journal:  Br J Clin Pharmacol       Date:  2002-01       Impact factor: 4.335

2.  Genotyping of four genetic polymorphisms in the CYP1A2 gene in the Egyptian population.

Authors:  Samar I Hamdy; Masahiro Hiratsuka; Kaori Narahara; Naomi Endo; Mervat El-Enany; Nadia Moursi; Mohammed S-E Ahmed; Michinao Mizugaki
Journal:  Br J Clin Pharmacol       Date:  2003-03       Impact factor: 4.335

3.  Determination of -3858G-->A and -164C-->A genetic polymorphisms of CYP1A2 in blood and saliva by rapid allelic discrimination: large difference in the prevalence of the -3858G-->A mutation between Caucasians and Asians.

Authors:  Liliane Todesco; Michael Török; Stephan Krähenbühl; Markus Wenk
Journal:  Eur J Clin Pharmacol       Date:  2003-07-08       Impact factor: 2.953

4.  Induction of CYP1A2 by heavy coffee consumption is associated with the CYP1A2 -163C>A polymorphism.

Authors:  Natasa Djordjevic; Roza Ghotbi; Slobodan Jankovic; Eleni Aklillu
Journal:  Eur J Clin Pharmacol       Date:  2010-07       Impact factor: 2.953

5.  Tacrine is not an ideal probe drug for measuring CYP1A2 activity in vivo.

Authors:  J T Larsen; L L Hansen; K Brosen
Journal:  Br J Clin Pharmacol       Date:  1999-11       Impact factor: 4.335

Review 6.  Molecular basis of polymorphic drug metabolism.

Authors:  A K Daly
Journal:  J Mol Med (Berl)       Date:  1995-11       Impact factor: 4.599

7.  Genome-wide association study identified SNP on 15q24 associated with bladder cancer risk in Japanese population.

Authors:  Koichi Matsuda; Atsushi Takahashi; Candace D Middlebrooks; Wataru Obara; Yasutomo Nasu; Keiji Inoue; Kenji Tamura; Ichiro Yamasaki; Yoshio Naya; Chizu Tanikawa; Ri Cui; Jonine D Figueroa; Debra T Silverman; Nathaniel Rothman; Mikio Namiki; Yoshihiko Tomita; Hiroyuki Nishiyama; Kenjiro Kohri; Takashi Deguchi; Masayuki Nakagawa; Masayoshi Yokoyama; Tsuneharu Miki; Hiromi Kumon; Tomoaki Fujioka; Ludmila Prokunina-Olsson; Michiaki Kubo; Yusuke Nakamura; Taro Shuin
Journal:  Hum Mol Genet       Date:  2014-10-03       Impact factor: 6.150

Review 8.  Idiosyncratic drug reactions. Metabolic bioactivation as a pathogenic mechanism.

Authors:  M Pirmohamed; S Madden; B K Park
Journal:  Clin Pharmacokinet       Date:  1996-09       Impact factor: 6.447

9.  Polymorphisms in the cytochrome P450 CYP1A2 gene (CYP1A2) in colorectal cancer patients and controls: allele frequencies, linkage disequilibrium and influence on caffeine metabolism.

Authors:  Christoph Sachse; Upinder Bhambra; Gillian Smith; Tracy J Lightfoot; Jennifer H Barrett; Jenna Scollay; R Colin Garner; Alan R Boobis; C Roland Wolf; Nigel J Gooderham
Journal:  Br J Clin Pharmacol       Date:  2003-01       Impact factor: 4.335

10.  Nonparametric expectation maximisation (NPEM) population pharmacokinetic analysis of caffeine disposition from sparse data in adult caucasians: systemic caffeine clearance as a biomarker for cytochrome P450 1A2 activity.

Authors:  Dimiter Terziivanov; Kristina Bozhinova; Velislava Dimitrova; Ivanka Atanasova
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.